Andrew has served in multiple senior scientific roles, including VP of Computational Chemistry at Expansion Therapeutics, Senior Director of CADD / cheminformatics at C4 Therapeutics, and Distinguished Scientific fellow at Genzyme. Andrew is a co-inventor on 14 projects that have led to IND candidate nomination including the HCV drugs Daclatasvir and Asunaprevir, resulting in a 2017 ACS heroes of chemistry award. He has pioneered several widely applied CADD techniques, including pharmacophore constraint usage, 3D pharmacophore fingerprints and Gaussian function approximations for molecular similarity calculations. Andrew has authored over 100 research articles and is a co-inventor on more than 50 patents.
